Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
9.19
+0.12 (1.32%)
Feb 21, 2025, 4:00 PM EST - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 17, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 84.98% from the current stock price of 9.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 2 | 2 | 3 |
| Hold | 2 | 2 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +84.98% | Feb 20, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +128.51% | Jan 15, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 13, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $12 | Buy → Hold | Downgrades | $17 → $12 | +30.58% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
538.64M
from 399.36M
Increased by 34.88%
Revenue Next Year
650.57M
from 538.64M
Increased by 20.78%
EPS This Year
-0.21
from -0.51
EPS Next Year
0.12
from -0.21
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 566.3M | 689.7M | 869.4M | |||
| Avg | 538.6M | 650.6M | 794.2M | |||
| Low | 514.0M | 600.2M | 700.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 41.8% | 28.0% | 33.6% | |||
| Avg | 34.9% | 20.8% | 22.1% | |||
| Low | 28.7% | 11.4% | 7.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.12 | 0.26 | 0.71 | |||
| Avg | -0.21 | 0.12 | 0.45 | |||
| Low | -0.25 | 0.02 | 0.32 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 511.7% | |||
| Avg | - | - | 281.6% | |||
| Low | - | - | 177.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.